BMC Medical Ethics, 2019 Background Much like academic-industry partnerships, industry financial support of patient advocacy organizations (PAOs) has become very common in recent years.
Orna Ehrlich +3 more
doaj +1 more source
Development of Mucosal PNAd+ and MAdCAM-1+ Venules during Disease Course in Ulcerative Colitis
Cells, 2020 PNAd and MAdCAM-1 addressins on venules are of importance in T-cell homing and potential therapeutic targets in ulcerative colitis (UC). Normally, PNAd+ high endothelial venules (HEVs) are only present in lymphoid organs, whereas small numbers of MAdCAM ...
Britt Roosenboom +10 more
doaj +1 more source
CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis. [PDF]
, 2015 As scientific techniques for the detection of cytomegalovirus (CMV) improve, we are able to detect small amounts of CMV in the mucosal wall. As clinicians, we are unsure how to interpret the results of this novel test.
Goodman, AL +4 more
core +1 more source
Recenti progressi in medicina, 2016 Inflammatory bowel disease (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are chronic, relapsing inflammatory disorders of the digestive tract resulting from dysregulated immune responses toward environmental factors in genetically predisposed individuals.
Lopetuso, Loris Riccardo +1 more
openaire +4 more sources
Ulcerative colitis: an update.
Clinical medicine (London), 2021 Ulcerative colitis is a relapsing and remitting disease that is increasing in incidence and prevalence. Management aims to achieve rapid resolution of symptoms, mucosal healing and improvement in a patient's quality of life.
J. Segal, J. LeBlanc, A. Hart
semanticscholar +1 more source
Serum antibodies in first-degree relatives of patients with IBD: A marker of disease susceptibility? A follow-up pilot-study after 7 years [PDF]
, 2005 Introduction: Various disease-specific serum antibodies were described in patients with inflammatory bowel disease and their yet healthy first-degree relatives.
H.P. Török +29 more
core +4 more sources
The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe
BMC Gastroenterology, 2021 Background Ulcerative colitis (UC) is an inflammatory bowel disease with increasing prevalence worldwide. Current treatment strategies place considerable economic and humanistic burdens on patients.
Leonardo Ruiz-Casas +14 more
doaj +1 more source
Anti-NMDAR encephalitis in Crohn’s disease undergoing long-term infliximab treatment: A case report
Frontiers in Immunology, 2022 Infliximab, a chimeric monoclonal antibody against anti-tumor necrosis factor-α (TNF-α), has revolutionized the management of inflammatory bowel disease. However, a recent nested case-control study showed that anti-TNF-α therapy exposure in patients with
Shin Ju Oh +3 more
doaj +1 more source
Current review of genetically modified lactic acid bacteria for the prevention and treatment of colitis using murine models [PDF]
, 2015 Inflammatory Bowel Diseases (IBD) are disorders of the gastrointestinal tract characterized by recurrent inflammation that requires lifelong treatments.
Azevedo, Vasco +7 more
core +1 more source
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
New England Journal of Medicine, 2019 BACKGROUND The efficacy of ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, as induction and maintenance therapy in patients with ulcerative colitis is unknown.
B. Sands +15 more
semanticscholar +1 more source